Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India

Back Stocks profile

Stock analysis tool for investors

Beta Drugs Ltd.

NSE: BETA | BSE:531481

₹1212.90 16.30 (1.36%) 1D

Pharmaceuticals & Biotechnology

Buy Sell

Open an Account with Bigul in 5 minutes

Performance

Today’s low

1188.50

Today’s High

1216.00

52W low

728.00

52W High

1595.00

Open Price

1190.20

Prev. Close

1259.5000

Volume

7200.00

Value

8732880.00

Fundamentals

Market Cap

1166.10

Price to Earnings

0.00

Price to Book Value

7.40

Dividend Yield

0.00

PE to Growth

0.00

Op Revenue TTM

0.00

Net Profit TTM

0.00

Cash From Operating Activity

30.93

Return on Equity %

23.19

EMA & SMA

Bullish Moving Averages

6

Bearish Moving Averages

10

5Day EMA

1206.6

10Day EMA

1208.4

12Day EMA

1209.7

20Day EMA

1215.4

26Day EMA

1220.3

50Day EMA

1238.3

100Day EMA

1249.7

200Day EMA

1195.5

5Day SMA

1205

10Day SMA

1206.7

20Day SMA

1219.2

30Day SMA

1220.2

50Day SMA

1244.4

100Day SMA

1264.3

150Day SMA

1308.1

200Day SMA

1241.6

DELIVERY AND VOLUME

DAILY AVG. DELIVERY VOLUME %

05 Jul, 2024

76.4

Week

77.3

Month

75.4

LEGEND

Positive Indicator

Neutral Indicator

Negative Indicator

RESISTANCE AND SUPPORT

1205.80

PIVOT

First Resistance

1223.10

Second Resistance

1233.30

Third Resistance

1250.60

First Support

1195.60

Second Support

1178.30

Third Support

1168.10

Relative Strength Index

48.04

Money Flow Index

50.5

MACD

-10.59

MACD Signal

-11.65

Average True Range

38.19

Average Directional Index

11.76

Rate of Change (21)

1.92

Rate of Change (125)

-14.63

Commodity Channel Index

-62.2

Williams %R

-49

BETA

1 Month

0.28

3 Month

-0.07

1 Year

0.38

3 Year

0.37

PRICE CHANGE ANALYSIS

↑ 0.24%

1 Week

Low

High

1188.5

1238

↓ -3.7%

1 Month

Low

High

1174.5

1285

↓ -12.11%

3 Months

Low

High

1100

1428

↓ -15.02%

6 Months

Low

High

1060.05

1524

↑ 54.02%

1 Year

Low

High

728

1595

Indicator Jun 2015 Mar 2015 Dec 2014 Sep 2014 Jun 2014 Mar 2014 Dec 2013 Sep 2013 Jun 2013 Mar 2013 Dec 2012 Graph
Total Qtr Revenue cr 0.01 0.01 0.01 0.01 0.02 0.04 0.07 0.06 0.05 0.05 0.04
Operating Expenses Qtr 0.00 0.00 0.00 0.01 0.00 0.04 0.06 0.05 0.04 0.05 0.03
Operating Profit Qtr 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01
EBIDT Qtr Cr 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01
Depreciation Qtr 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Profit Qtr 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.00 0.00
Basic EPS Qtr 0.00 0.00 0.01 0.01 0.01 0.00 0.01 0.01 0.01 0.01 0.01
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 199.35 158.92 125.70 80.07 65.74
Operating Expenses Annual Cr 164.10 126.68 99.66 64.15 53.57
Operating Profit Annual 33.53 31.20 25.18 15.31 11.75
Operating Profit Margin Annual % 16.82 19.63 20.03 19.12 17.88
Total Expenses Annual Cr 169.87 133.71 105.54 70.19 56.79
EBIDT Annual Cr 35.26 32.24 26.04 15.92 12.17
EBIDT Annual margin % 17.68 20.29 20.72 19.88 18.51
Depreciation 4.72 6.19 5.47 5.27 2.58
PAT Before ExtraOrdinary Items Annual Cr 21.94 18.82 14.25 6.98 7.10
Net Profit Annual 21.94 18.82 14.25 6.98 7.10
Basic EPS Annual 22.82 19.57 14.82 7.26 7.49
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 116.01 96.26 77.46 63.42 56.44
Minority Interest Liability Annual Cr - - - - -
Total Non Current Liabilities Annual Cr 6.80 6.32 7.59 4.45 4.34
Total Current Liabilities Annual Cr 47.66 31.47 25.85 18.36 21.44
Total Capital Plus Liabilities Annual Cr 170.47 134.04 110.90 86.23 82.21
Fixed Assets Annual 36.48 34.77 34.06 29.91 31.75
Total Non Current Assets Annual 56.80 49.04 48.14 42.29 45.05
Total Current Assets Annual 113.67 85.00 62.76 43.94 37.17
Total Assets Annual 170.47 134.04 110.90 86.23 82.21
Contingent Liabilities plus Commitments Annual Cr - 0.74 0.66 0.51 0.27
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 21.19 10.23 18.76 11.60 6.09
Cash from Investing Activity Annual -11.02 -5.82 -12.72 -3.15 -14.33
Cash from Financing Annual Activity -0.76 -2.19 1.27 -4.34 9.48
Net Cash Flow Annual - 2.21 7.31 4.10 1.24
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 120.67 100.12 80.57 65.96 58.71
ROE Annual % 18.90 19.54 18.39 11.00 12.57
ROCE Annual % 24.86 25.39 24.19 15.69 15.77
Total Debt to Total Equity Annual 0.03 0.04 0.07 0.06 0.13
EBDIT Annual Margin % 17.83 20.42 20.85 20.03 18.62
Indicator Graph
Total Qtr Revenue cr
Operating Expenses Qtr
Operating Profit Qtr
EBIDT Qtr Cr
Depreciation Qtr
Net Profit Qtr
Basic EPS Qtr
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total Revenue Annual 297.07 227.87 184.59 116.62 91.22
Operating Expenses Annual Cr 235.72 173.99 141.14 91.38 72.90
Operating Profit Annual 60.00 53.13 42.70 24.75 17.91
Operating Profit Margin Annual % 20.20 23.32 23.13 21.22 19.63
Total Expenses Annual Cr 248.32 186.81 150.29 100.67 79.24
EBIDT Annual Cr 61.36 53.88 43.45 25.24 18.32
EBIDT Annual margin % 20.65 23.65 23.54 21.65 20.08
Depreciation 9.78 10.41 7.25 6.87 3.76
PAT Before ExtraOrdinary Items Annual Cr 36.44 30.72 24.83 11.72 9.42
Net Profit Annual 36.44 30.72 24.83 11.72 9.42
Basic EPS Annual 37.90 31.95 25.82 12.20 9.93
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Total ShareHolders Funds Annual 157.12 122.88 92.34 68.61 57.11
Minority Interest Liability Annual Cr 0.00 0.00 0.00 0.00 0.00
Total Non Current Liabilities Annual Cr 12.31 12.52 16.54 14.53 13.37
Total Current Liabilities Annual Cr 84.67 63.02 48.97 34.36 36.69
Total Capital Plus Liabilities Annual Cr 254.10 198.42 157.85 117.51 107.18
Fixed Assets Annual 64.59 62.76 54.95 42.78 43.90
Total Non Current Assets Annual 76.23 70.74 60.89 48.97 51.14
Total Current Assets Annual 177.87 127.68 96.96 68.53 56.04
Total Assets Annual 254.10 198.42 157.85 117.51 107.18
Contingent Liabilities plus Commitments Annual Cr - 0.77 1.77 1.59 0.73
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Cash from Operating Activity Annual 30.93 23.38 29.63 18.60 8.41
Cash from Investing Activity Annual -13.97 -19.07 -21.75 -5.85 -15.05
Cash from Financing Annual Activity -7.49 -2.47 -0.97 -7.71 8.73
Net Cash Flow Annual - 1.84 6.90 5.04 2.09
Indicator Mar 2024 Mar 2023 Mar 2022 Mar 2021 Mar 2020 Graph
Book Value Per Share Annual 163.43 127.82 96.05 71.37 59.41
ROE Annual % 23.19 24.99 26.88 17.08 16.48
ROCE Annual % 30.43 32.10 33.24 22.09 20.65
Total Debt to Total Equity Annual 0.07 0.13 0.18 0.21 0.35
EBDIT Annual Margin % 20.74 23.72 23.63 21.73 20.17
Name Holding Percent Holding Id Pledged % Locked %
Ashish Kacholia 5.78 75290083 - -
Suryavanshi Commotrade Private Limited 6.74 75290087 - -
Name Holding Percent Holding Id Pledged % Locked %
Neeraj Batra 65.96 75290072 0 0
Name Holding Percent Holding Id
Name Holding Percent Holding Id
Ashish Kacholia 5.78 75290083
Onkar Singh 1.05 75290084
HUF 0.71 75290091
Suryavanshi Commotrade Private Limited 6.74 75290087
Bsas Infotech Limited 1.27 75290088
Ex-Date Dividend Amount Dividend Type Record Date Instrument Type
Ex-Date Split Ratio Record Date
Ex-Date Purpose Notes
May 14, 2024 Audited Results -
Nov 07, 2023 Quarterly Results & Others To consider the Migration of the Equity shares of the Company from Emerge-SME Platform of National Stock Exchange of India Limited ( NSE Emerge ) to the Main board of NSE and BSE.
May 08, 2023 Audited Results -
Oct 27, 2022 Quarterly Results -
Apr 27, 2022 Audited Results -
Oct 25, 2021 Quarterly Results -
Apr 27, 2021 Audited Results -
Oct 19, 2020 Quarterly Results -
Jun 17, 2020 Others To consider Fund Raising
May 28, 2020 Audited Results -
Oct 23, 2019 Quarterly Results -
May 29, 2019 Others To consider & approve the acquisition of Adley Lab Limited, a promoter company who is manufacturer & major supplier of API to Beta Drugs Limited & Adley Formulations Private Limited.
May 13, 2019 Audited Results -
May 01, 2019 Others To consider other business matters
Mar 28, 2019 To consider raising of funds -
Dec 12, 2018 Other business matters -
Sep 26, 2018 Others To incorporate a wholly owned subsidiary of Beta Drugs Ltd. named Adley Formulations Pvt Ltd.
Sep 06, 2018 Other business matters -
Aug 17, 2018 Other business matters -
May 08, 2018 Audited Results -
Apr 20, 2018 Others To consider Fund Raising anFund Raising/Other business mattersnd other business matters.
Mar 14, 2018 Other Business Matters -
Jan 03, 2018 Others To avail financial assistance of Rs 100.00 lacs by way of Machinery loan from SIDBI, Sector-17 Chandigarh.
Ex-Date Bonus Ratio Record Date
15 May 2024

Beta Drugs Results Earnings Call for Q4FY24

 Conference Call with Beta Drugs Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.
07 Dec 2021

Business Update: Beta Drugs

 Conference Call with Beta Drugs Management and Analysts on recent Business Updates. Listen to the full transcript.
06 May 2021

Earnings Call for Q4FY21 of Beta Drugs

 Conference Call with Beta Drugs Management and Analysts on Q4FY21 Performance and Outlook. Listen to the full earnings transcript.
See all News

FAQs

The latest market price of Beta Drugs Ltd. on NSE was Rs. 1212.90 as of today.

The opening share price of Beta Drugs Ltd. was Rs. 1190.20 as of today.

The 52-week high share price of Beta Drugs Ltd. was Rs. 1595.00.

The 52 week low share price of Beta Drugs Ltd. was Rs. 728.00.

Please find Corporate actions section for more details.

The PE ratio of Beta Drugs Ltd. is 0.00. Please refer to the Fundamentals section for further details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please refer to Stock Ants, Bigul’s Community Access platform that aggregates tips and research from experts and provides real-time tracking to help investors validate, discover new investment ideas, and make informed decisions. Click here to learn more.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please find Corporate actions section for more details.

Please refer to Bigul Traders Corner, One Stop destination for different algo and non-algo trading strategies and tools meant for investors, traders, and strategists. Our qualified experts with rich experience in broking, financial analysis, and software development designed it in-house. Click here to learn more.

Please refer to JARVIS, which is Bigul’s AI Portfolio Manager Tool that uses artificial intelligence algorithms to make investment decisions in a portfolio. Click here to learn more.

Please refer to the News section for the latest news about Beta Drugs Ltd..

Close

Let's Open Free Demat Account